Drug Combination Details
| General Information of the Combination (ID: C79203) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Recombinant mutant human TRAIL Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ADAR | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | AIFM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CAPNS1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CBX3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HNRNPK | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ILF3 | Molecule Info | |||
| Up-regulation | Expression | PCBP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | STAT1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | THRAP3 | Molecule Info | |||
| In-vitro Model | RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
| U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
ATO and rmhTRAIL had synergistic or additive effects on proliferation inhibition and apoptosis induction in MM cells, and the mechanism underlying the two-drug combination might involve regulation of the expression of several proteins affected by ATO and rmhTRAIL. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Exp Hematol. 2016 Feb;44(2):125-131.e11. | |||
